

 Early Warning System

IFC-47180

Tridem Africa



## Quick Facts

Countries	Ivory Coast
Financial Institutions	International Finance Corporation (IFC)
Status	Approved
Bank Risk Rating	B
Voting Date	2023-06-05
Borrower	SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Sectors	Education and Health
Investment Type(s)	Loan
Investment Amount (USD)	\$ 54.76 million
Project Cost (USD)	\$ 98.56 million



---

## Project Description

According to the Bank's website, Tridem Pharma SAS, together with Guilin Pharma, are planning to expand their pharmaceutical production capacity and distribution capabilities in French-speaking Africa through the construction of a regional pharmaceutical distribution hub in Cote d'Ivoire and the greenfield construction of a local drug manufacturing facility in Cote d'Ivoire (the "Project"). The manufacturing facility in Cote d'Ivoire will primarily be used to manufacture life-saving anti-malaria drugs. The proposed IFC investment comprises of two A loans to the local subsidiaries of Tridem and Guilin Pharma for the implementation of the Project.

Tridem is a French pharmaceutical distribution company with a substantial presence in Africa, which offers distribution solutions for pharmaceutical manufacturers, including regulatory affairs and licensing, promotion, distribution. Guilin Pharma is a Chinese pharmaceutical company and a leading producer of anti-malarial products, with its products being made available in over 80 countries globally.



---

## Investment Description

- International Finance Corporation (IFC)



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Guilin Pharmaceutical Co Ltd.	Subsidiary	-
-	-	-	-	Shanghai Fosun Pharmaceutical (Group) Co. Ltd.	Client	-
-	-	-	-	Tridem Pharma SAS	Subsidiary	-



---

## Contact Information

Tridem Pharma  
Leon Sheng  
Deputy General Manager  
+86 (21) 6013 3949  
l.sheng@tridem-pharma.com  
Rm. 1101, BLDG B, #1289 Yishan Rd. Shanghai 200233  
www.tridem-pharma.com

## ACCESS TO INFORMATION

You can submit a request for information disclosure at: <https://disclosures.ifc.org/#/inquiries>

If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.

## ACCOUNTABILITY MECHANISM OF IFC/MIGA

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at [CAO@worldbankgroup.org](mailto:CAO@worldbankgroup.org) You can learn more about the CAO and how to file a complaint at <http://www.cao-ombudsman.org>



---

## Bank Documents

- [Environmental & Social Review Summary \(ESRS\)](#)